Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Fineline Cube Aug 19, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Fineline Cube Aug 19, 2026
Company Drug

HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study

Fineline Cube Jul 26, 2023

Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...

Company Deals

Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal

Fineline Cube Jul 26, 2023

Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...

Company Drug

InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study

Fineline Cube Jul 26, 2023

Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease

Fineline Cube Jul 26, 2023

Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...

Company

Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts

Fineline Cube Jul 26, 2023

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...

Company Drug

FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment

Fineline Cube Jul 25, 2023

The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...

Company Drug

Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results

Fineline Cube Jul 25, 2023

Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for...

Policy / Regulatory

EU Commits EUR 3 Million to Strengthen Healthcare Access in Latin America and Caribbean

Fineline Cube Jul 25, 2023

The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection...

Company Drug

AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico

Fineline Cube Jul 25, 2023

Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...

R&D

Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population

Fineline Cube Jul 25, 2023

Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive...

Company Deals

Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment

Fineline Cube Jul 25, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...

Company Deals

Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program

Fineline Cube Jul 25, 2023

Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...

Company Drug

Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial

Fineline Cube Jul 25, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...

Company Drug

Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment

Fineline Cube Jul 25, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...

Company Policy / Regulatory

Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments

Fineline Cube Jul 25, 2023

The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...

Company Drug

Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review

Fineline Cube Jul 25, 2023

US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development

Fineline Cube Jul 25, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...

Company Drug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Fineline Cube Jul 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...

Medical Device Policy / Regulatory

NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China

Fineline Cube Jul 25, 2023

The National Medical Products Administration (NMPA) has released an updated version of the “List of...

Policy / Regulatory

Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023

Fineline Cube Jul 25, 2023

The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...

Posts pagination

1 … 542 543 544 … 710

Recent updates

  • Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China
  • Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists
  • FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19
  • Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting
  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Company Medical Device

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.